Table 2 Associations between EMVI and clinical risk predictors in validation cohort
Characteristics | EMVI (−) (N = 4) | EMVI (+) (N = 3) |
|---|---|---|
Age, mean ± SD, years | 77.00 ± 5.48 | 70.00 ± 13.75 |
Sex, N (%) | ||
Male | 4 (100) | 3 (100) |
Female | 0 (0) | 0 (0) |
BMI, mean ± SD, kg/m2 | 22.40 ± 1.86 | 21.12 ± 4.92 |
CEA | ||
≤ 5 ng/mL, N (%) | 4 (100) | 1 (33.33) |
> 5 ng/mL, N (%) | 0 (0) | 2 (66.67) |
CA19-9 | ||
≤ 34 U/mL, N (%) | 4 (100) | 3 (100) |
> 34 U/mL, N (%) | 0 (0) | 0 (0) |
Distance, mean ± SD, mm | 85.00 ± 20.82 | 99.67 ± 22.14 |
cT N (%) | ||
T1 | 0 (0) | 0 (0) |
T2 | 0 (0) | 0 (0) |
T3 | 3 (75.00) | 1 (33.33) |
T4a | 1 (25.00) | 2 (66.67) |
T4b | 0 (0) | 0 (0) |
cN N (%) | ||
Negative | 1 (25.00) | 1 (33.33) |
Positive | 3 (75.00) | 2 (66.67) |
LN, median, N | 3.5 | 3 |
MR-EMVI, N (%) | ||
Negative | 3 (75.00) | 3 (100) |
Positive | 1 (25.00) | 0 (0) |
MR-CRM, N (%)* | ||
Negative | 4 (100) | 3 (100) |
Positive | 0 (0) | 0 (0) |